Fanconi Anemia Differential Diagnoses
- Author: Jeffrey M Lipton, MD, PhD; Chief Editor: Jennifer Reikes Willert, MD more...
Patients with Fanconi anemia with characteristic birth defects (eg, radial ray anomalies, poor growth, genitourinary abnormalities) are often treated by various medical specialists during infancy. The diagnosis of Fanconi anemia must first be considered and can only be established if specific tests are ordered.
Failure to diagnose aplastic anemia or leukemia may lead to delays in treatment. The diagnosis of Fanconi anemia must be made to avoid the inappropriate use of immunosuppressive therapy for aplastic anemia, the use of toxic levels of chemotherapy or radiotherapy in leukemia or solid tumors, or toxic types of preparation for stem cell transplantation.
Patients who have tumors that are characteristic of Fanconi anemia but who present without the usual risk factors for those tumors need to be screened for Fanconi anemia (eg, head and neck cancer in a 20-year-old woman who does not smoke or drink).
Mild forms of Fanconi anemia may be missed, placing future pregnancies in that family at risk for Fanconi anemia. Possible probands with characteristic birth defects, undiagnosed cytopenias, or macrocytosis should be evaluated for Fanconi anemia.
Differentials to consider in the diagnosis of Fanconi anemia, aside from those in the next section, include the following conditions:
Acquired aplastic anemia
Acute myeloid leukemia
In utero viral infections
Teratogens should also be considered in the diagnosis.
Katzenellenbogen RA, Carter JJ, Stern JE, et al. Skin and mucosal human papillomavirus seroprevalence in persons with fanconi anemia. Clin Vaccine Immunol. 2015 Apr. 22 (4):413-20. [Medline].
Alter BP, Kupfer G. Fanconi anemia. Pagon RA, Bird TD, Dolan CR, et al, eds. Gene Reviews. Seattle, Wash: University of Washington; 2013.
Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003 Feb 1. 101(3):822-6. [Medline].
Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica. 2008 Apr. 93(4):511-7. [Medline].
Tipping AJ, Pearson T, Morgan NV, et al. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc Natl Acad Sci U S A. 2001 May 8. 98(10):5734-9. [Medline]. [Full Text].
Callén E, Casado JA, Tischkowitz MD, et al. A common founder mutation in FANCA underlies the world's highest prevalence of Fanconi anemia in Gypsy families from Spain. Blood. 2005 Mar 1. 105(5):1946-9. [Medline].
Verlander PC, Kaporis A, Liu Q, Zhang Q, Seligsohn U, Auerbach AD. Carrier frequency of the IVS4 + 4 A-->T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. Blood. 1995 Dec 1. 86(11):4034-8. [Medline].
Rosenberg PS, Socié G, Alter BP, Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood. 2005 Jan 1. 105(1):67-73. [Medline].
Sauter SL, Wells SI, Zhang X, et al. Oral human papillomavirus is common in individuals with Fanconi anemia. Cancer Epidemiol Biomarkers Prev. 2015 May. 24 (5):864-72. [Medline].
Dalle JH. HSCT for Fanconi anemia in children: factors that influence early and late results. Bone Marrow Transplant. 2008 Oct. 42 Suppl 2:S51-3. [Medline].
Pasquini R, Carreras J, Pasquini MC, et al. HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. Biol Blood Marrow Transplant. 2008 Oct. 14(10):1141-7. [Medline]. [Full Text].
MacMillan ML, DeFor TE, Young JA, et al. Alternative donor hematopoietic cell transplantation for Fanconi anemia. Blood. 2015 Jun 11. 125 (24):3798-804. [Medline].